Welcome to our dedicated page for L A M Y SEC filings (Ticker: LMMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on L A M Y's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into L A M Y's regulatory disclosures and financial reporting.
L A M Y reported that it has completed the acquisition of Exousia Ai, Inc., a Florida clinical-stage biotechnology company developing plant-based exosome therapies, by issuing 62,223,000 shares of its common stock to Exousia Ai’s two shareholders. Following the closing on November 17, 2025, Exousia Ai became a wholly owned subsidiary and Exousia Pro Holding Management, LLC now owns 41,223,000 shares, representing about 58.89% of L A M Y’s 70,000,000 shares outstanding as of that date, resulting in a change of control and a shift in strategy to exosome-based biotech, cosmeceutical and nutraceutical products. Matthew Dwyer replaced Zhang Shengwu as sole officer and director, and the combined company highlights that Exousia Ai has received FDA Orphan Drug Designation for an exosome-based treatment for glioblastoma, while cautioning that it is early-stage, loss-making, under-capitalized and faces significant competition and financing, regulatory and penny‑stock market risks.
LAMY filed its quarterly report for the three months ended August 31, 2025, showing it remains a development-stage company with no operating revenue. The company reported a net loss of $31,814 for the quarter, compared with a net loss of $3,911 in the same period of 2024, driven mainly by professional fees, OTC market fees, and advertising expenses. As of August 31, 2025, LAMY reported total assets of $0 and total liabilities of $35,314, all current and largely due to related-party advances, resulting in a stockholders’ deficit of $35,314. The accumulated deficit since inception reached $63,584, and management states there is substantial doubt about the company’s ability to continue as a going concern. LAMY has 7,777,000 common shares outstanding and plans to rely on equity and/or debt financing and continued related-party support to fund operations, with no committed financing arrangements in place.
LAMY (LMMY)
Revenue was
The auditor issued a going concern opinion citing limited operations and an accumulated deficit of
FAQ
What is the current stock price of L A M Y (LMMY)?
What is the market cap of L A M Y (LMMY)?
